Table 4 Univariable and multivariable analysis of factors associated with response to etanercept for polyarticular RF-negative and enthesitis-related JIA
Baseline characteristics | Poor vs Intermediate and Excellent Responders | Excellent vs Intermediate and Poor Responders | ||||||
|---|---|---|---|---|---|---|---|---|
Univariable analysis | Multivariable analysis | Univariable analysis | Multivariable analysis | |||||
Odds ratio (95% CI) | p value | Odds ratio (95% CI) | p value | Odds ratio (95% CI) | p value | Odds ratio (95% CI) | p value | |
Polyarticular RF-negative JIA | ||||||||
Demographic | ||||||||
Gender | 0.886 (0.519-1.461) | 0.642 | 1.334 (0.765-2.283) | 0.295 | ||||
Disease duration before start of etanercept | 0.55 (0.312-0.917) | 0.027 | 0.313 (0.116-0.730) | 0.012 | 0.995 (0.573-1.818) | 0.985 | ||
Age of disease onset | 0.659 (0.391-1.087) | 0.106 | 0.418 (0.176-0.866) | 0.028 | 1.535 (0.84-3.14) | 0.193 | 0.518 (0.267-0.945) | 0.039 |
Disease activity | ||||||||
CHAQ score at start of etanercept | 0.58 (0.321-0.984) | 0.053 | 0.801 (0.300-2.108) | 0.649 | 1.745 (0.982-3.255) | 0.065 | 1.089 (0.469-2.543) | 0.841 |
VAS disease activity by patient/parent at start of etanercept | 0.946 (0.565-1.562) | 0.828 | 1.1 (0.617-1.934) | 0.741 | ||||
VAS disease activity by physician at start of etanercept | 0.76 (0.436-1.266) | 0.308 | 1.375 (0.785-2.444) | 0.261 | ||||
No. of joints with LOM | 0.575 (0.328-0.96) | 0.041 | 0.438 (0.150-1.129) | 0.103 | 2.081 (1.069-4.712) | 0.049 | 0.430 (0.185-0.900) | 0.033 |
Morning stiffness, min | 0.505 (0.259-0.876) | 0.026 | 0.524 (0.214-1.130) | 0.121 | 4.592 (1.54-20.62) | 0.021 | 0.680 (0.326-1.312) | 0.267 |
Previous therapy | ||||||||
No. of DMARDs used before start of etanercept | 0.638 (0.366-1.065) | 0.095 | 1.272 (0.558-3.069) | 0.573 | 0.707 (0.386-1.253) | 0.243 | ||
Fact of biologics using before start of etanercept | 0.696 (0.42-1.146) | 0.155 | 0.604 (0.283-1.224) | 0.170 | 0.891 (0.513-1.589) | 0.685 | ||
Laboratory tests | ||||||||
CRP at start of etanercept | 0.712 (0.41-1.171) | 0.189 | 0.658 (0.304-1.333) | 0.252 | 3.361 (1.166-19.326) | 0.088 | 0.539 (0.271-0.959) | 0.046 |
Enthesitis-related JIA | ||||||||
Demographic | ||||||||
Gender | - | - | 0.6 (0.242-1.365) | 0.226 | ||||
Disease duration before start of etanercept | 0.17 (0.021-0.59) | 0.029 | 3.980 (1.294-23.095) | 0.048 | 3.219 (0.995-19.183) | 0.12 | 0.385 (0.051-1.531) | 0.263 |
Age of disease onset | 2.286 (0.885-7.397) | 0.114 | 0.404 (0.13-1.002) | 0.073 | 1.200 (0.308-5.023 | 0.789 | ||
Previous therapy | ||||||||
No. of DMARDs used before start of etanercept | 0.737 (0.275-1.816) | 0.51 | 3.587 (1.261-15.132) | 0.039 | 0.351 (0.047-1.416) | 0.205 | ||
Fact of biologics using before start of etanercept | 0.419 (0.161-0.997) | 0.056 | 2.030 (0.714-6.369) | 0.185 | 2.052 (0.81-8.276) | 0.184 | 1.046 (0.220-4.252) | 0.948 |